Autobio Diagnostics (603658) investor relations material

Executive summary

• Revenue for H1 2026 was RMB 2.06 billion, down 0.12% year-over-year; net profit attributable to shareholders was RMB 497 million, down 12.94%.

• R&D investment reached RMB 401 million, accounting for 19.5% of revenue, with continued expansion in product lines and international markets.

• The company maintained a strong innovation pipeline, with 48 new reagent product registrations and 3 new instrument registrations.

• Overseas business expanded to 120+ countries, with local operations in Indonesia and enhanced global brand presence.

Financial highlights

• Operating income: RMB 2,057,927,123.10 (down 0.12% YoY).

• Net profit attributable to shareholders: RMB 497,124,027.29 (down 12.94% YoY).

• Operating cash flow: RMB 215,841,961.03 (down 47.38% YoY).

• Basic and diluted EPS: RMB 0.87 (down 14.71% YoY).

• Gross margin: 67.2% (calculated from revenue and cost figures).

• R&D expenses: RMB 302,352,829.31 (up 20.77% YoY).

Outlook and guidance

• The company aims to accelerate transformation into a digital diagnostics solutions provider, focusing on high-end product breakthroughs, market penetration, and cost optimization.

• International expansion and local market adaptation remain key, with further investments in R&D and supply chain efficiency.

• No interim dividend or capital increase from reserves proposed for the half-year.